Montaur has now invested $13 million in the Dublin, OH-based firm.
In other Neoprobe news, the company said that a phase III trial of its Lymphoseek radiopharmaceutical found a concordance rate of 96% with Lymphoseek and patient blue dyes. The trial studied the use of Lymphoseek in breast cancer and melanoma patients.
Neoprobe gets OK for Lymphoseek study, April 16, 2008
Neoprobe announces phase II Lymphoseek results, March 13, 2008
Neoprobe nets financing, December 27, 2007
Neoprobe extends agreement with Ethicon, December 20, 2007
Neoprobe, Cardinal Health ink distribution deal, November 28, 2007
Copyright © 2008 AuntMinnie.com